SCHEMBL29126

SCHEMBL29126

C=C(OC(=C)C(C)Cl)C(C)Cl

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78483 0.72
SCHEMBL2339042 0.71
SCHEMBL13192911 0.71
SCHEMBL84210 0.69 ALDH1A1 (0.33) ALDH1A1
SCHEMBL11575460 0.67
SCHEMBL4627087 0.67
SCHEMBL7158083 0.67
SCHEMBL11804104 0.67
SCHEMBL6903741 0.67
SCHEMBL11129029 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3075750-B1 METHOD FOR PREPARING VINYL CHLORIDE-BASED RESIN HANWHA CHEMICAL CORP (KR) 2020-01-08 EP claimed
US-9637580-B2 Method for preparing vinyl chloride-based resin HANWHA CHEMICAL CORPORATION (KR) 2017-05-02 US claimed
US-20160376387-A1 METHOD FOR PREPARING VINYL CHLORIDE-BASED RESIN HANWHA CHEMICAL CORPORATION (KR) 2016-12-29 US claimed
EP-3075750-A1 METHOD FOR PREPARING VINYL CHLORIDE-BASED RESIN Hanwha Chemical Corporation (KR) 2016-10-05 EP claimed
US-20260144848-A1 METHOD FOR PREDICTING RESPONSE TO A CANCER TREATMENT PEPTOMYC, S.L. (ES) 2026-05-28 US disclosed
EP-4724083-A1 COMBINATION THERAPY WITH BRAF INHIBITORS FOR THE TREATMENT OF CANCER Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (ES) 2026-04-15 EP disclosed
EP-4724082-A1 OMOMYC AND KRAS INHIBITORS COMBINATION THERAPY FOR THE TREATMENT OF CANCER Peptomyc, S.L. (ES) 2026-04-15 EP disclosed
EP-4724100-A1 COMBINATION THERAPY WITH MEK INHIBITORS FOR THE TREATMENT OF CANCER Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (ES) 2026-04-15 EP disclosed
EP-4720172-A1 SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL Forschungszentrum Jülich GmbH (DE) 2026-04-08 EP disclosed
EP-4695608-A1 METHOD FOR ASSESSING OR MONITORING THE RESPONSE TO A CANCER TREATMENT Peptomyc, S.L. (ES) 2026-02-18 EP disclosed
WO-2025262249-A1 PREVENTION OF COGNITIVE-DECLINE DISORDERS DERIVED FROM RADIOTHERAPY UNIVERSIDAD DE NAVARRA (ES) 2025-12-26 WO disclosed
WO-2025242796-A1 HYDROGENATED SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENE-ANION EXCHANGE POLYMERS AS MEMBRANE MATERIALS FOR ALKALINE WATER ELECTROLYSIS AND FUEL CELLS Forschungszentrum Jülich GmbH (DE) 2025-11-27 WO disclosed
US-4314043-A POLYSILOXANE-ADDITION COPOLYMERS ASAHI GLASS COMPANY, LTD. (JP) 1982-02-02 US disclosed
WO-1980002839-A1 CURABLE ORGANIC RESIN COMPOSITIONS AND FOAMING METHOD GEN ELECTRIC 1980-12-24 WO disclosed
US-4239725-A CATIONICALLY POLYMERIZABLE IN THE PRESENCE OF A CATALYST OF A DIARYL IODONIUM SALT, A COPPER SALT AND A REDUCING AGENT GENERAL ELECTRIC COMPANY (US) 1980-12-16 US disclosed
US-4237258-A CONTAINING MINOR AMOUNTS OF ETHYLENICALLY UNSATURATED MONOMERS; MOLDING MATERIAL MONTEDISON S.P.A. (IT) 1980-12-02 US disclosed
US-4225691-A DIARYLDIIODONIUM SALTS GENERAL ELECTRIC COMPANY (US) 1980-09-30 US disclosed
US-4192924-A DIARYLIOPONIUM SALT REDOX CATALYST GENERAL ELECTRIC COMPANY (US) 1980-03-11 US disclosed
US-4083725-A CINNAMIC ACID PHOTOSENSITIVE RESIN AND A HALOGEN SUBSTITUTED BENZANTHRONE SENSITIZER MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1978-04-11 US disclosed
US-4063953-A POLYETHERS, POLYEPICHLOROHYDRIN, VINYL CINNAMATES MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JA) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144848-A1 METHOD FOR PREDICTING RESPONSE TO A CANCER TREATMENT SELE, SELL, SELPLG ALDH1A1 1786/4885TSHR 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.